

NUCLEAR REGULATORY COMMISSION
DOCKET NO. 030-33923
November 26, 2004

Environmental Assessment Related to an Amendment
of U.S. Nuclear Regulatory Commission Materials License No. 37-30241-01,
Issued to ViroPharma, Incorporated

The U.S. Nuclear Regulatory Commission (NRC) is considering terminating Materials License Number 37-30241-01 and authorizing the release of the licensee's facilities in Exton, Pennsylvania, for unrestricted use and has prepared an Environmental Assessment (EA) in support of this action.

SUMMARY: The NRC reviewed the results of the decommissioning of the ViroPharma, Incorporated facility in Exton, Pennsylvania. ViroPharma, Incorporated was authorized by NRC from December 17, 1997 to use radioactive materials for research and development purposes at the site. In 2004, ViroPharma, Incorporated ceased operations with licensed materials at the Exton site, and requested that NRC terminate the license. ViroPharma, Incorporated has conducted surveys of the facility and determined that the facility meets the license termination criteria in Subpart E of 10 CFR Part 20. The NRC staff has evaluated ViroPharma, Incorporated's request and the results of the surveys, and has developed an EA in accordance with the requirements of 10 CFR Part 51. The NRC has determined that a Finding of No Significant Impact (FONSI) is appropriate for the proposed action.

Introduction

ViroPharma, Incorporated requested release for unrestricted use of the building at 405 Eagleview Boulevard, Exton, Pennsylvania as authorized by the NRC License No. 37-30241-01, and termination of the license. The building is 87,000 square feet of general office and laboratory space located in a commercial office park area. Within this building, radioactive material was used in approximately 13,000 square feet of laboratory and storage space.

License No. 37-30241-01 was issued in 1995 and amended periodically since that time. NRC-licensed activities performed at the Exton site were authorized in 1997, and were limited to laboratory procedures typically performed on bench tops and in hoods using hydrogen-3, carbon-14, sulphur-35, phosphorus-32, and phosphorus-33. No outdoor areas were affected by the use of licensed materials.

Licensed activities ceased completely in June, 2004 and the licensee requested release of the facility for unrestricted use and termination of the license. Based on the licensee's historical knowledge of the site and the conditions of the facility, the licensee determined that only routine decontamination activities, in accordance with licensee radiation safety procedures, were required. A decommissioning plan was not required to be submitted to the NRC. The licensee surveyed the facility, decontaminated or remediated areas as needed, and provided documentation that the facility meets the license termination criteria specified in Subpart E of 10 CFR Part 20, and does not require additional decommissioning activities to be performed. The licensee demonstrated this using the screening criteria described in 65 FR 37186. The

licensee subsequently requested that the facility be released for unrestricted use and that the license be terminated.

The Proposed Action

The proposed action is to terminate Materials License No. 37-30241-01 and release the facility at 405 Eagleview Boulevard, Exton, Pennsylvania for unrestricted use. By letter dated July 28, 2004, ViroPharma, Incorporated stated that no further actions are required to remediate the facility and provided survey results which demonstrate that the Exton facility is in compliance with the radiological criteria for license termination in Subpart E, 10 CFR Part 20, "Radiological Criteria for License Termination."

Purpose and Need for the Proposed Action

The purpose of the proposed action is to amend NRC Materials License No. 37-30241-01, to allow for the release of 405 Eagleview Boulevard in Exton, Pennsylvania for unrestricted use and terminate the license. The licensee needs this license change because it no longer plans to conduct licensed activities at this facility. NRC is fulfilling its responsibilities under the Atomic Energy Act to make a timely decision on a proposed license amendment for release of facilities for unrestricted use and termination of a license that ensures protection of public health and safety and the environment. The licensee has requested the action to reduce their regulatory burden since they no longer intend to conduct licensed activities at this location.

Environmental Impacts of the Proposed Action

The affected environment was described in the Introduction. The licensee has completed all remediation at the site. The NRC staff has reviewed the surveys performed by ViroPharma, Incorporated to demonstrate compliance with the 10 CFR 20.1402 license termination criteria. Based on its review, the staff has determined that the affected environment and environmental impacts associated with the release for unrestricted use of the ViroPharma, Incorporated facilities are bounded by the impacts evaluated by the "Generic Environmental Impact Statement in Support of Rulemaking on Radiological Criteria for License Termination of NRC-Licensed Nuclear Facilities" (NUREG-1496). The staff also finds that the proposed release for unrestricted use of the ViroPharma, Incorporated facilities is in compliance with Title 10, Code of Federal Regulations, Part 20.1402, "Radiological Criteria for Unrestricted Use." The NRC has found no other activities in the area that could result in cumulative impacts.

Environmental Impacts of the Alternatives to the Proposed Action

Since the facility at the Exton site has already been surveyed and found acceptable for release for unrestricted use, the only alternative to the proposed action of termination of the license and release of the Exton site for unrestricted use is no action. The no-action alternative is not acceptable because the licensee does not plan to perform any activities with licensed materials at these locations and does not plan to maintain staff to perform licensed activities. Maintaining

ViroPharma, Incorporated
Environmental Assessment

the areas under a license would impose an unnecessary regulatory burden. The effect of the no-action alternative would be to restrict potential benefits from future uses of the site.

Agencies and Persons Consulted

The NRC staff has determined that the proposed action will not affect listed species or critical habitat. Therefore, no further consultation is required under Section 7 of the Endangered Species Act. Likewise, the NRC staff have determined that the proposed action is not the type of activity that has the potential to cause effects on historic properties. Therefore, no further consultation is required under Section 106 of the National Historic Preservation Act.

NRC provided a draft of its Environmental Assessment to the Pennsylvania Bureau of Radiation Protection for review. On November 18, 2004, the Pennsylvania Department of Environmental Protection Bureau of Radiation Protection responded by email and agreed with the conclusions of the EA.

Conclusions

Based on its review, the NRC staff has concluded that the completed action complies with 10 CFR Part 20. The NRC staff have prepared this EA in support of the proposed action to terminate License No. 37-30241-01. On the basis of the EA, NRC has concluded that there are no significant environmental impacts and the license amendment does not warrant the preparation of an Environmental Impact Statement. Accordingly, it has been determined that a Finding of No Significant Impact is appropriate.

List of Preparers

Marjorie McLaughlin, Health Physicist, Division of Nuclear Materials Safety, Region I

List of References

1. NRC License No. 37-30241-01 inspection and licensing records.
2. Final Status Survey Results for ViroPharma, Incorporated, 405 Eagleview Boulevard, Exton, Pennsylvania, dated July, 2004 [ADAMS Accession No. ML042230034].
3. Federal Register Notice, Volume 65, No. 114, page 37186, dated Tuesday, June 13, 2000, "Use of Screening Values to Demonstrate Compliance With The Federal Rule on Radiological Criteria for License Termination."
4. Title 10 Code of Federal Regulations, Part 20, Subpart E, "Radiological Criteria for License Termination."
5. Title 10, Code of Federal Regulations, Part 51, "Environmental Protection Regulations for Domestic Licensing and Related Regulatory Functions."

ViroPharma, Incorporated
Environmental Assessment

6. NUREG-1496, "Generic Environmental Impact Statement in Support of Rulemaking on Radiological Criteria for License Termination of NRC-Licensed Nuclear Facilities."

The application for the license amendment and supporting documentation are available for inspection at NRC's Public Electronic Reading Room at <http://www.nrc.gov/reading-rm/adams.html>. Any questions with respect to this action should be referred to Marjorie McLaughlin, Decommissioning Branch, Division of Nuclear Materials Safety, Region I, 475 Allendale Road, King of Prussia, Pennsylvania 19406, telephone (610) 337-5240, fax (610) 337-5269.

Dated at King of Prussia, Pennsylvania this 26th day of November, 2004

FOR THE NUCLEAR REGULATORY COMMISSION

James P. Dwyer, Chief
Commercial & R&D Branch
Division of Nuclear Materials Safety
Region I

ViroPharma, Incorporated
Environmental Assessment

DOCUMENT NAME: E:\Filenet\ML043310216.wpd

To receive a copy of this document, indicate in the box: "C" = Copy w/o attach/encl "E" = Copy w/ attach/encl "N" = No copy

OFFICE	DNMS/RI	<input type="checkbox"/> N	DNMS/RI	<input type="checkbox"/> N				
NAME	MmcLaughlin MMM3	Jdwyer JPD1						
DATE	11/19/04	11/26/04						

OFFICIAL RECORD COPY